Functionalized N-(2-oxyiminoethyl) piperazinyl quinolones as new cytotoxic agents

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 10, Issue 2, 2007, Pages 152-157

  Rajabalian, Saeed ^a   Foroumadi, Alireza ^a,b   Shafiee, Abbas ^b   Emami, Saeed ^c  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CIPROFLOXACIN; CYTOTOXIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; ETOPOSIDE; N [2 (FURAN 2 YL) 2 OXYIMINOETHYL]PIPERAZINYLQUINOLONE; N [2 (THIOPHEN 2 YL) 2 OXYIMINOETHYL]PIPERAZINYLQUINOLONE; NORFLOXACIN; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN MCF 7; CYTOTOXICITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION;

EID: 34249302775     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Piddock L. J. V., Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs, 58 (Suppl. 2): 11-18, 1999.
2. Drlica K. and Zhao X., DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev, 61: 377-392, 1997.
3. Drlica K., Mechanism of fluoroquinolone action. Curr Opin Microbiol, 2: 504-508, 1999.
4. Drlica K. and Zhao X., DNA topoisomerase IV as a quinolone target. Curr Opin Antiinfect Investig Drugs, 1: 435-442, 1999.
5. Wang J. C., DNA topoisomerases. Annu Rev Biochem, 65: 635-692, 1996.
6. Burden D. A. and Osheroff N., Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochem Biophys Acta, 1400: 139-154, 1998.
7. Coughlin S. A., Danz D. W., Robinson R. G., Klingbeil K. M., Wentland M. P., Corbett T. H., Waud W. R., Zwelling L. A., Altschuler E., Bales E. and Rake J. B., Mechanism of action and antitumor activity of (S)-10-(2,6-dimethyl-4-pyridinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7 H- pyridol[1,2,3-de]-[1,4]benzothiazine-6-carboxylic acid (WIN 58161). Biochem Pharmacol, 50: 111-122, 1995.
8. Clement J. J., Burres N., Jarvis K., Chu D. T., Swiniarski J. and Alder J., Biological characterization of a novel antitumor quinolone. Cancer Res, 55: 830-835, 1995.
9. Anderson V. E. and Osheroff N., Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Curr Phann Design, 7: 339-353, 2001.
10. Sissi C. and Palumbo M., The quinolone family: from antibacterial to anticancer agents. Curr Med Chem Anti-Cancer Agents, 3: 439-450, 2003.
11. Robinson M. J., Martin B. A., Gootz T. D., McGuirk P. R., Moynihan M., Sutcliffe J. A. and Osheroff N., Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. J Biol Chem, 266: 14585-14592, 1991.
12. Robinson M. J., Martin B. A., Gootz T. D. McGuirk P. R. and Osheroff N., Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Antimicrob Agents Chemother, 36: 751-756, 1992.
13. Elsea S. H., McGuirk P. R., Gootz T. D., Moynihan M. and Osheroff N., Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Antimicrob Agents Chemother, 37: 2179-2186, 1993.
14. Foroumadi A., Emami S., Haghighat P. and Moshafi M. H., Synthesis and in-vitro antibacterial activity of new N-substituted piperazinyl quinolones. Pharm Pharmacol Commun, 5: 591-594, 1999.
15. Mirzaei M. and Foroumadi A., Synthesis and in-vitro antibacterial activity of N-piperazinyl quinolone derivatives with a 2-thienyl group. Pharm Pharmacol Commun, 6: 351-354, 2000.
16. Mosmann T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 65: 55-63, 1983.
17. Foroumadi A., Emami S., Mehni M., Moshafi M. H. and Shafiee A., Synthesis and antibacterial activity of N-[2-(5-bromothiophen-2-yl)-2-oxoethyl] and N-[(2-5-bromothiophen-2-yl)-2-oxyiminoethyl] derivatives of piperazinyl quinolones. Bioorg Med Chem Lett, 15: 4536-4539, 2005.
18. Nikaido H. and Vaara M., Molecular basis of bacterial outer membrane permeability. Microbiol Rev, 49: 1-32, 1985.
19. Neves P., Berkane E., Gameiro P., Winterhalter M. and de Castro B., Interaction between quinolones antibiotics and bacterial outer membrane porin OmpF. Biophys Chem, 113: 123-128, 2005.
20. Alovero F., Pan X.-S., Morris J. E., Manzo R. H. and Fisher L. M., Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob Agents Chemother, 44: 320-325, 2000.